Vice President, Translational Medicine

Sarah is Vice President, Translational Medicine, and Global Program Lead at Chroma Medicine. Previously, Sarah led the preclinical and translational development of autologous Treg cell therapy products for autoimmune diseases at Abata Therapeutics. Prior to that, Sarah oversaw preclinical and translational development from discovery through marketing approval of autologous T cell products for oncology, as well as HSC products for severe genetic diseases at bluebird bio. Sarah started her career at Novartis, working in Discovery and Investigative Safety, where she led a laboratory using molecular, cellular and biochemical approaches to study pharmacologic and toxicologic drug mechanisms. Sarah obtained her PhD from The Scripps Research Institute, where she researched in vitro evolution of catalytic RNAs.